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1. Introduction
Diagnostic  and  therapeutic  angiographic  procedures  are  increasingly  performed.  Many
complex interventions  are  lengthy and require  large  dosages  of  contrast  medium (CM).
Radiological  procedures such as  coronary angiography require  intravascular  administra‐
tion of iodinated CM is becoming a great source of an iatrogenic disease known as con‐
trast-induced  nephropathy  (CIN).  The  pathogenesis  of  CIN  is  unclear.  The  proposed
mechanisms are outer-medullary hypoxia due to decreased renal blood flow secondary to
renal artery vasoconstriction. Tubular obstruction, apoptosis and oxidative damage, endo‐
thelial dysfunction, defective prostaglandin synthesis, and autonomic dysfunction are oth‐
er proposed mechanisms.
Patients  who  develop  CIN  have  higher  complication  rates,  longer  hospital  stays,  and
higher  mortality  than  patients  who  not  develop  CIN.  Nearly  one-third  of  the  patients
who require in-hospital dialysis because of CIN die prior to discharge. No current treat‐
ment can reverse or ameliorate CIN once it occurs. The occurrence of CIN is directly re‐
lated  to  the  number  of  pre-existing  patient  risk  markers.  After  the  high-risk  patient
population has been identified and risk markers  addressed,  the next  step in preventing
CIN is  the  use  of  different  prophylactic  therapies.  The strongly  associated risk  markers
for CIN are pre-existing renal failure, diabetes mellitus, age greater than 70 years, concur‐
rent use of nephrotoxic drugs, hypovolemia, use of a large amount of CM or an ionic hy‐
perosmolar CM, and congestive heart failure.
Aim of the present chapter is to summarize the knowledge about the risk factors and pro‐
phylactic treatments of CIN according to the ultimate clinical research and developments.
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2. Definition of CIN
A universally accepted definition of CIN does not exist. The most commonly used definition
for CIN is the elevation of serum creatinine by ≥0.5mg/dl or ≥25% occurring within 48 hours
after administration of CM, and the absence of an alternative etiology. Using the Cockcroft-
Gault and the Modification of Diet in Renal Disease equations are useful in estimation of the
GFR. Serum cystatin C has been proposed as an alternative endogenous marker of GFR
showing higher correlation to standard clearance methods such as inulin or iohexol clear‐
ance. Serum cystatin C may detect CIN one to two days earlier than creatinine. Recent stud‐
ies documented that serum and urine neutrophil gelatinase-associated lipocalin is an early
predictive biomarker of CIN (Shaker et al., 2010). Urinary interleukin 18 and urinary liver-
type fatty acid-binding protein are new potential biomarkers of CIN (Perrin et al., 2012).
Cholesterol atheroemboli, volume depletion, and interstitial nephritis should consider in
differential diagnosis of CIN. The incidence of CIN is reported to be 0.6-2.3% in general pop‐
ulation who do not have any risk factor for CIN, but the incidence can be increased to 90%
in patients at high risk for CIN (Toprak, 2007).
2.1. Pathophysiology of CIN
The potential pathophysiologic mechanisms of CIN were summarized in Figure 1. Medul‐
lary hypoxia due to decreased renal blood flow secondary to renal artery vasoconstriction,
tubular obstruction, direct tubular toxicity of the CM due to apoptosis, oxidative damage,
endothelial dysfunction, and renal microcirculatory alterations may play a role in the patho‐
genesis of CIN.
2.2. Clinical course and outcomes
CIN may range in severity from asymptomatic, nonoliguric transient renal dysfunction to
oliguric severe renal failure that necessitates permanent dialysis. CIN is reported to be the
third leading cause of in-hospital acute renal failure after hypotension and surgery. Approx‐
imately $180 million is spent annually to manage CIN in the US. Dangas et al. showed that
in-hospital outcomes such as death (6.3% vs 0.8%), cardiac death (4.0% vs 0.5%), coronary
artery bypass grafting (5.8% vs 0.5%), major adverse cardiac event (9.3% vs 1.1%), packed
red cell transfusion (28% vs 6%), vascular surgery of access site (5.6% vs 2.6%), post-proce‐
dure length of stay (6.8±7.1 vs 2.3±2.5) were significantly higher in CIN developed patients
compare with control (p<0.0001). In cumulative one-year outcome death, out-of-hospital
death and major adverse cardiac events were significantly higher in CIN developed patients
(p<0.0001) (Dangas et al., 2005). In a study of acute myocardial infarction patients undergo‐
ing primary angioplasty, it was found that CIN developed patients have significantly higher
incidence of high-rate atrial fibrillation (p=0.01), high-degree conduction disturbances re‐
quiring permanent pacemaker (p=0.04), acute pulmonary edema (p=0.008), respiratory fail‐
ure requiring mechanical ventilation (p<0.0001), cardiogenic shock requiring intra-aortic
balloon (p<0.0001), and acute renal failure requiring renal replacement therapy (p<0.0001)
(Marenzi et al., 2004).
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Figure 1. Pathogenesis of contrast-induced nephropathy. NO: nitric oxide.
2.3. Risk Factors for CIN
Specific factors that increase the risks for development of CIN are related to the patient, the
contrast media, and the procedure (Table 1).
Risk Factors Odds Ratio (95%CI) p Value
Kidney Related Risk Factors
Pre-existing renal failure
Preprocedural creatinine 2.0-2.9 mg/dl 7.37 (4.78-11.39) <0.0001
Preprocedural creatinine ≥ 3mg/d 12.82 (8.01-20.54) <0.0001
Diabetes mellitus-Diabetic nephropathy
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Risk Factors Odds Ratio (95%CI) p Value
Preprocedural creatinine≤ 1.1mg/dl 1.86 (1.20-2.89) 0.005
Preprocedural creatinine 1.2-1.9 mg/dl 2.42 (1.54-3.79) <0.001
Use of nephrotoxic drugs
Low effective circulatory volume 1.19 (0.72-1.95) 0.05
Cardiovascular System Related Risk Factors
Class III-IV congestive heart failure 2.20 (1.60-2.90) <0.0001
Left ventricle ejection fraction<40% 1.57 (1.14-2.16) 0.005
Acute myocardial infarction ≤ 24 h 1.85 (1.31-2.63) 0.0006
Hypertension 2.00 (1.40-2.80) 0.0001
Periprocedural hypotension 2.50 (1.70-3.69) <0.00001
Multi-vessel coronary involvement 3.24 (1.07-9.82) 0.038
Peripheral vascular disease 1.90 (1.40-2.70) <0.0001
Preprocedure shock 1.19 (0.72-1.96) 0.05
Using intra-aortic balloon pump 15.51 (4.65-51.64) <0.0001
Bypass graft intervention 4.94 (1.16-20.9) 0.03
Time-to-reperfusion ≥6 h 2.51 (1.01-6.16) 0.04
Pulmonary edema 2.56 (1.42-4.52) 0.001
Demographic Risk Factors
Age "/>75 years 5.28 (1.98-14.05) 0.0009
Female gender 1.4 (1.25-1.60) 0.0001
Contrast Media Related Risk Factors
High total dose of contrast agent ("/>300 ml) 2.8 (1.17-6.68) 0.02
Osmolality (Low- vs. high-osmolality) 0.50 (0.36-0.68)
Short duration of two contrast administration 4.4 (2.9-6.5) <0.0001
Other Possible Risk Factors
Procedural success 0.27 (0.19-0.38) <0.0001
Baseline hematocrit 0.95 (0.92-0.97) <0.00001
Hyperuricemia 4.71 (1.29-17.21) 0.019
ACE inhibitors 3.37 (1.14-9.94) 0.028
Angiotensin Receptor Blockers 2.70 (1.25-5.81) 0.011
Metabolic Syndrome 426 (1.19-15.25) 0.026
Hypoalbuminemia 5.79 (1.71-19.64) 0.005
Hypercholesterolemia
Renal transplant
Multiple myeloma
Diuretics
Intra-arterial contrast administration
Sepsis, cirrhosis
Table 1. Risk factors for the development of contrast-induced nephropathy
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2.3.1. Patient-related risk factors
2.3.1.1. Pre-existing renal disease
The major risk factor for CIN is a GFR<60 ml/min/1.73 m2.  Chronic kidney disease is as‐
sociated  with  decreased  vasodilatory  response,  which  is  important  in  developing  CIN,
and in  patients  with  renal  insufficiency,  the  clearance  of  CM is  slower  than  in  normal
subjects.  In  a  study of  7586  patients  who underwent  coronary intervention,  CIN devel‐
oped in 22.4% of the patients who had serum creatinine levels of 2.0 to 2.9 mg/dl and in
30.6% of those with serum creatinine levels of 3.0 mg/dl or higher, compared with 2.4%
of patients with serum creatinine levels <1.1 mg/dl ( Rihal et al.,  2002). Two other stud‐
ies (Moore et  al.,  1992;  Barrett  et  al.,  1992) reported that the incidence of CIN increased
from 4% to 20% as the baseline serum creatinine increased from 1.2 to 2.9 mg/dl. In an‐
other study, the incidence of CIN increased from 8% to 92% as the serum creatinine in‐
creased  from  1.5  to  6.8  mg/dl.  Furthermore,  the  probability  of  CIN  requiring  dialysis
increases  from  0.04%  to  48%  as  the  baseline  GFR  decreases  from  50  to  10  ml/min
(McCullough et al., 1997).
2.3.1.2. Diabetes mellitus
Nitric  oxide-dependent  renal  vasodilatation  is  characteristically  altered  and  renal  outer
medullary pO2  is  significantly reduced in diabetes mellitus.  Chronic kidney disease and
DM  are  associated  with  endothelial  dysfunction  and  decreased  vasodilatory  responses.
Diabetic  nephropathy has been identified as a powerful  and independent risk factor for
CIN. Patients with diabetic nephropathy and a mean serum creatinine of 6.8 mg/dl had a
92% incidence of CIN after coronary angiography (Weinrauch et al.,  1977). Patients with
diabetes who have advanced chronic renal  failure because of  causes other than diabetic
nephropathy are at significantly higher risk of developing CIN like diabetic nephropathy.
On the other hand,  studies have shown that  when pre-existing renal  disease is  present,
patients with and without diabetes are similarly at risk of CIN, which correlates with the
degree of renal disease. Some authors have suggested that DM in the absence of nephrop‐
athy,  particularly  in  insulin-dependent  patients  with  diabetes,  is  associated  with  an  in‐
creased risk of CIN (McCullough et al., 1997; Toprak 2007). In a study, it was found that
the incidence of CIN was rather low (2%) in patients with neither diabetes nor azotemia,
significantly higher (16%) in individuals with diabetes but preserved renal function, and
much higher (38%) in patients who had both diabetes and azotemia (Lautin et al., 1991).
In another study, the incidence of CIN was found to be 2% in patients without diabetes
and  3.7%  in  patients  with  diabetes  with  a  baseline  creatinine  of  1.1  mg/dl  or  less
(OR=1.86, p=0.005). When renal function is mildly impaired (serum creatinine level 1.2 to
1.9 mg/dl), the risk of CIN in patients with diabetes mellitus increases to 4.5% (OR=2.42,
p<0.001) (Rihal et al., 2002). Other studies have failed to corroborate this connection (Par‐
frey  et  al.,  1989).  However,  given  that,  those  with  diabetes  alone  were  found  to  be  at
slightly higher risk of CIN than the general population.
Contrast-Induced Nephropathy
http://dx.doi.org/10.5772/54032
325
2.3.1.3. Pre-diabetes
In a study of 421 patients who underwent coronary angiography with renal insufficiency,
we presented that pre-DM increase the incidence of CIN 2.1-fold in comparison to patients
with normal fasting glucose (NFG) but pre-DM is not as strong as DM as a risk of develop‐
ing CIN. CIN occurred in 20% of the DM (RR=3.6, p=0.001), 11.4% of the pre-DM (RR 2.1,
p=0.314) and 5.5% of the NFG group. The decrease of GFR was higher in DM and pre-DM
(p=0.001 and p=0.002, respectively). Length of hospital stay was 2.45 ± 1.45 day in DM, 2.27 ±
0.68 day in pre-DM, and 1.97 ± 0.45 day in NFG (p<0.001, DM vs. NFG and p=0.032, pre-DM
vs. NFG). The rate of major adverse cardiac events was 8.7% in DM, 5% in pre-DM, and
2.1% in NFG (P=0.042, DM vs. NFG). Hemodialysis was required in 3.6% of DM, and 0.7% in
pre-DM (P=0.036, DM vs. NFG), and the total number of hemodialysis sessions during 3
months was higher in DM and pre-DM (P<0.001). Serum glucose ≥124 mg/dl was the best
cut-off point for prediction of CIN (Toprak et al., 2007).
2.3.1.4. Metabolic syndrome, impaired fasting glucose and hypertriglyceridemia
In a prospective cohort study of 219 non-diabetic elderly patients with reduced kidney func‐
tion who underwent elective coronary angiography, we reported that metabolic syndrome
was a risk indicator of CIN (OR=4.26, p=0.026). CIN occurred in 14% of the metabolic syn‐
drome group and 3.6% of the non-metabolic syndrome group (relative risk 3.93, p=0.007).
Impaired fasting glucose (OR=4.72, p=0.007), high triglyceride (OR=4.06, p=0.022); and multi-
vessel involvement (OR=3.24, p=0.038) in the metabolic syndrome group were predictors of
CIN (Toprak et al., 2006).
2.3.1.5. Hyperuricemia
Contrast agents have a uricosuric effect, which appears to be caused by enhanced renal tub‐
ular secretion of uric acid. Furthermore, hyperuricemia is accompanied by enhanced synthe‐
sis of reactive oxygen species, tubular obstruction by uric acid, an activated renin–
angiotensin–aldosterone system, increased endothelin-1, and an inhibited nitric oxide sys‐
tem which plays a role in the pathogenesis of CIN. In a prospective cohort study we evaluat‐
ed 266 patients who undergoing elective coronary angiography and we found that patients
with hyperuricemia are at risk of developing CIN (OR=4.71, p=0.019). CIN occurred in 15.1%
of the hyperuricemic group and 2.9% of the normouricemic group (p<0.001). Length of hos‐
pital stay (p<0.001) and CIN requiring renal replacement therapy (p=0.017) were significant‐
ly higher in hyperuricemic group. Serum uric acid ≥7 mg/dl in males and ≥5.9 mg/dl in
females were found the best cut-off value for prediction of CIN (Toprak et al., 2006).
2.3.1.6. Hypercholesterolemia
Altered nitric oxide-dependent renal vasodilatation is prevalent in hypercholesterolemia.
Hypercholesterolemia aggravates CIN through the reduced production of nitric oxide (Yang
et al., 2004).
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2.3.1.7. Multivessel Coronary involvement, peripheral vascular disease, and renal artery stenosis
If a patient has multivessel coronary involvement, the other vessels in the body, such as
the renal artery,  can be involved. If  the renal artery is  involved, the renal blood supply
may decrease and the kidneys may be more susceptible to CIN. Factors related to acceler‐
ated  or  diffuse  atherosclerosis  are  linked to  the  development  of  CIN.  The  treatment  of
multivessel  disease,  challenging  chronic  total  occlusions  and  extensively  diseased  coro‐
nary segments,  may require  high doses  of  CM for  providing an optimal  image quality,
thus enhancing the potential toxic effects on the renal function. In a study of 177 patients
who  underwent  cardiac  catheterization,  subjects  were  also  evaluated  for  renal  artery
stenosis. Coronary artery disease was detected in 110 patients (62%), and significant renal
artery  stenosis  was  detected  in  19  patients  (11%).  Using  multivariate  analysis,  it  was
found that the extent of coronary artery disease was an independent predictor of renal ar‐
tery  stenosis  (Weber-Mzell  et  al.,  2002).  In  a  study a  total  of  5571  patients  who under‐
went PCI were evaluated for CIN risk factors, and it was found that multivessel coronary
involvement  was  only  a  univariate  predictor  of  CIN (p=0.003)  (Mehran et  al.,  2004).  In
two other cohort studies it was found that peripheral vascular disease is a risk for CIN in
patients who underwent PCI (OR=1.9, p<0.0001 and OR=1.71, p=0.001, respectively) (Bar‐
tholomew et  al.,  2004;  Rihal  et  al.,  2002).  In a study a total  of  219 non-diabetic  patients
who underwent coronary angiography we have found that multivessel coronary involve‐
ment is a risk for CIN (OR=3.24, p=0.038) (Toprak et al., 2006).
2.3.1.8. Older age
In a prospective study in which elderly patients (≥70 years) were subjected to cardiac cathe‐
terization, 11% developed CIN (Rich & Crecelius, 1990). In another study, CIN incidence
was 17% in elderly patients (>60 years) as compared with 4% in younger patients (Kohli et
al., 2000). In 208 patients with acute myocardial infarction who underwent coronary inter‐
vention, it was found that an age of ≥75 years was an independent risk for CIN (OR=5.28,
p=0.0009) (Marenzi et al., 2004). The possible reasons of the high incidence of CIN in elderly
were age-related changes in renal function, more difficult vascular access following tortuosi‐
ty, calcification of the vessels requiring greater amount of CM, defective prostaglandin syn‐
thesis, and the presence of renovascular disease. Furthermore, hypovolemia is very common
in elderly patients.
2.3.1.9. Gender
Ovarian hormones can affect the renin–angiotensin system and renal blood flow. In a retro‐
spective study of 8628 patients who underwent PCI, female sex was an independent predic‐
tor of CIN (OR=1.4, p<0.0001). One-year outcome analyses by gender showed a higher
mortality among females than among males in a cohort of CIN patients (14% vs 10%, p=0.05)
(Iakovou et al., 2003). The findings of this study contradict those of a previous randomized
controlled trial of ionic vs nonionic CM, in which a multivariate analysis identified male
gender as an independent risk factor for CIN (Rudnick et al., 1995).
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2.3.1.10. Hypovolemia
Hypovolemia leads to active sodium reabsorbtion, which is an oxygen-demanding process,
and increases neurohumoral vasoconstrictive stimuli that might compromise medullary
oxygenation. The toxic effects of CM on the renal tubular lumen may be exacerbated in hy‐
povolemia. Decreased effective circulating volume and reduced renal perfusion potentiate
renal vasoconstriction after administration of intravascular CM. Volume expansion reduces
the activity of the renin–angiotensin system, minimizes increases in blood viscosity and os‐
molality, and increases medullary perfusion. At present the most convincing preventive
procedure of CIN is adequate hydration with isotonic saline or sodium bicarbonate. Before
coronary angiography, the volume status of patients can be assessed through the inferior
vena cava index, mean atrial pressure, noninvasive pulmonary-capillary wedge pressure or
bioimpedance spectroscopy (Toprak & Cirit, 2005).
2.3.1.11. Congestive heart failure and reduced left ventricular ejection fraction
Advanced heart failure and reduced LVEF are characterized by effective volume depletion
caused by low cardiac output and increased neurohumoral vasoconstrictive stimuli and im‐
paired nitric oxide-dependent renal vasodilatation that might compromise medullary oxy‐
genation. Studies have shown that reduced left ventricular ejection fraction (LVEF) (≤49%)
and advanced congestive heart failure (New York Heart Association class III or IV) are inde‐
pendent risk factors for CIN. In a study, Dangas et al. showed that LVEF below 40% is an
independent predictor of CIN (Dangas et al., 2005). We have previously reported that if the
LVEF is greater than 30%, this condition does not show any significant effect on the devel‐
opment of CIN (Toprak et al., 2003). In a study it was shown that congestive heart failure
was an independent risk for CIN (OR=1.53, p=0.007) (Rihal et al., 2002). In a cohort study it
was found that congestive heart failure is a risk for CIN in patients who underwent PCI
(OR=2.2, p<0.0001) (Bartholomew et al., 2004).
2.3.1.12. Hypertension
An explanation for hypertension as a risk factor for CIN is: alterations in the intrarenal ex‐
pression of vasoactive mediators, such as the renin-angiotensin system or nitric oxide, may
be contributing factors. Impaired nitric oxide-dependent renal vasodilatation is prevalent in
individuals who are hypertensive. Finally, a reduced number of nephrons could predispose
hypertensive patients to CIN. In a study of 8628 patients who underwent percutaneous in‐
terventions, hypertension was found to be an independent predictor of CIN (OR=1.2,
p=0.0035). In a cohort study Bartholomew et al. found that hypertension is a risk for CIN in
patients who underwent PCI (OR=2.0, p=0.0001) (Bartholomew et al., 2004).
2.3.1.13. Nephrotoxic drugs
Directly, nephrotoxic drugs and those that inhibit the vasodilatory effects of prostaglandins
have been reported to render the kidney more vulnerable to CM. Sulfonamides, aminogly‐
cosides, and their combinations with furosemide are particularly potent. Cyclosporin A may
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intensify medullary hypoxia, and cisplatin can attach to sulfhydryl groups. Mannitol can in‐
crease the metabolic workload in the kidney, and amphotericin B can cause the effect of a
combination of mannitol and cyclosporine A. Nonselective NSAIDs and selective COX-2 in‐
hibitors decrease the vasodilatory prostaglandins in the kidney and potentiate the vasocon‐
strictive effect of CM.
2.3.1.14. Metformin
Patients who are receiving metformin may develop lactic acidosis as a result of CIN. A de‐
cline in renal function after contrast exposure could adversely affect the clearance of metfor‐
min. The complication was almost always observed in diabetic patients with decreased renal
function before injection of CM. A meta-analysis by the Cochrane Library with pooled data
from 176 comparative trials and cohort studies revealed no cases of fatal or nonfatal lactic
acidosis in 35,619 patient-years of metformin use or in 30,002 patients-years in the non-met‐
formin group. It seems safer to instruct patients especially at high risk for CIN not to take
this drug for 48 h or so after CM administration and resume taking the drug only if there are
no signs of nephrotoxicity.
2.3.1.15. ACE inhibitors and angiotensin receptor blockers
ACE inhibitors have been identified as a risk factor for CIN because of their potential to re‐
duce renal function. On the other hand, some small studies have shown that the nephrotox‐
icity of CM may be reduced because of decreased renal vasoconstriction by inhibition of
angiotensin II. Renal vasoconstriction occurs after the CM administration and the renin–an‐
giotensin system is responsible for this vasoconstriction. In a randomized controlled study
with 71 patients with diabetes who underwent coronary angiography randomized to capto‐
pril or control, 25-mg captopril was given three times daily. There was a significant decrease
in CIN in the patients who received captopril compared with the control group (6% vs 29%,
respectively, p<0.02) (Gupta et al., 1999). We have performed a randomized controlled study
in 80 patients with serum creatinine below 2 mg/dl who underwent coronary angiography.
Captopril was administered in 48 patients before coronary angiography. Five patients
(10.4%) in the captopril group developed CIN, compared with only one patient (3.1%) in the
control group (p=0.02) (Toprak et al., 2003). In a study of 230 patients with renal insufficien‐
cy and age ≥65 years we found that chronic ACE inhibitor administration was a risk for de‐
veloping CIN. CIN occurred in 17 patients (15.6%) in the ACE inhibitor group and 7 patients
(5.8%) in the control group (p=0.015). Serum creatinine level increased from 1.34 ± 0.20 to
1.53 ± 0.27 mg/dl in the ACE inhibitor group and from 1.33 ± 0.18 to 1.45 ± 0.19 mg/dl in the
control group (p<0.001). Chronic ACE inhibitor administration was a risk indicator of CIN
(OR=3.37, p=0.028) (Cirit et al., 2006). In another study, 421 patients with renal insufficiency
who underwent coronary angiography, use of ACE inhibitors or ARB was a risk for CIN in
multivariate analysis (OR=2.7, p=0.011) (Toprak et al., 2007). In a recent study, the impact of
renin-angiotensin and aldosterone system blockade on the frequency of CIN was assessed
retrospectively. Patients treated with ACE inhibitors or ARB (n=269) and were not treated
with them (n=143) underwent coronary angiography included to the study. CIN developed
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11.9% in ACE-inhibitor using group and 4.2% in control group (p=0.006). Use of ARB or
ACE inhibitors was found as a risk for CIN (OR=3.08, p=0.016) (Kiski et al., 2010). Checking
the use of ACE inhibitors or ARB before coronary angiography seems to be a useful guide in
tracking risk assessment for CIN. It is reasonable to suggest that there is a need to hold ACE
inhibitor or ARB use before coronary angiography.
2.3.1.16. Multiple myeloma
Multiple myeloma has been suggested as a potential risk factor for CIN. The pathomechan‐
ism of this process has been explained by the precipitation of CM molecules together with
Tamm–Horsfall proteins and other abnormal proteins, tubular epithelial cells damaged and
desquamated as a result of ischemia, direct contrast toxicity, or disturbed function of integ‐
rins. Intratubular light chains, particularly in the setting of intravascular volume depletion,
have been found to augment the nephrotoxic potential of CM (Holland et al., 1985). Studies
with a broader scope have since shown that the observed risk is linked to coexisting risk fac‐
tors, such as pre-existing renal insufficiency, low circulating volume, proteinuria, amyloido‐
sis, hyperuricemia, and hypercalcemia rather than to myeloma itself. Studies showed an
incidence of CIN of only 0.6–1.25% in patients with myeloma if dehydration is avoided (Mc‐
Carthy & Becker, 1992).
2.3.1.17. Renal transplantation
Patients with renal transplantation may be at a higher risk of CIN due to concomitant use of
cyclosporine and higher prevalence of diabetes and renal insufficiency. In a study, 33 pa‐
tients with a functioning renal allograft who underwent different contrast studies, the inci‐
dence of CIN was 21.2% (Ahuja et al., 2000).
2.3.1.18. Acute myocardial infarction
A study by Rihal et al. showed that acute myocardial infarction within 24 h before adminis‐
tration of the CM is a risk factor for CIN (OR=1.85, p=0.0006). This study demonstrates that
CIN is a frequent complication in acute myocardial infarction, even in patients with a nor‐
mal baseline renal function. (Rihal et al., 2002). In a study of 208 acute myocardial infarction
patients who underwent primary PCI, anterior acute myocardial infarction was significantly
higher in patients who developed CIN (p=0.0015). However, in multivariate analysis, anteri‐
or acute myocardial infarction (OR=2.17, p=0.09) was not a risk for CIN (Marenzi et al.,
2004). In 2082 percutaneous interventions for acute myocardial infarction, it was reported a
more than seven-fold (3.2% vs 23.3%) increase in 1-year mortality in patients who developed
CIN (Sadeghi et al., 2003).
2.3.1.19. Anemia
Anemia-induced deterioration of renal ischemia may be one plausible explanation for the
higher incidence of CIN in patients with a low hematocrit level. A baseline hematocrit value
of less than 39% for men and less than 36% for women is a risk for CIN. The relationship
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between low hematocrit levels and CIN has been investigated in a prospective study of 6773
patients who underwent PCI (Nikolsky et al., 2005). A lower baseline hematocrit was an in‐
dependent predictor of CIN; and each 3% decrease in baseline hematocrit resulted in a sig‐
nificant increase in the odds of CIN in patients with and without chronic kidney disease
(11% and 23%, respectively). Dangas et al. showed that the baseline hematocrit level is an
independent predictor of CIN in patients with chronic kidney disease (OR=0.95, p<0.00001)
(Dangas et al., 2005).
2.3.1.20. Low serum albumin
Hypoalbuminemia impairs endothelial  function, enhances renal vasoconstriction, impairs
the synthesis and release of nitric oxide, and decreases antioxidant enzyme activity. In a
study, low serum albumin (<3.5 g/dl)  was identified as a risk factor for CIN in patients
70 years of age or older who underwent cardiac catheterization (Rich, et al.,  1990).  Also
we have found that in 230 patients who underwent coronary angiography with renal in‐
sufficiency,  serum albumin level  ≤3.5  g/dl  was  a  risk  factor  for  CIN (OR=5.79,  p=0.005)
(Cirit et al., 2006).
2.3.1.21. Hypotension, sepsis, cirrhosis, and pulmonary edema
A systolic blood pressure of less than 80 mm Hg for at least 1 h that requires inotropic
support with medications is a risk factor for CIN. A study by Dangas et al showed that
periprocedural hypotension and pulmonary edema are independent predictors of CIN in
patients  with  chronic  kidney disease  (OR=2.50,  p<0.00001  and OR=2.56,  p=0.001,  respec‐
tively) (Dangas et al., 2005) Sepsis, through direct damage by bacterial toxins to renal tu‐
bules  and impairment  of  circulation,  has  also  been reported as  a  risk  factor.  Reduction
of effective intravascular volume caused by liver cirrhosis has been reported as contribu‐
ting to pre-renal reduction in renal perfusion, thus enhancing the ischemic insult of CM
(Toprak, 2007).
2.3.2. Procedure-related risk factors
2.3.2.1. Short duration of the two contrast administration and urgent/emergency procedure
In those who have no risk factors for CIN, angiography should be delayed more than 48
hours after a previous exposure to intravascular contrast media. In patients with diabetes or
preexisting renal disease, this time interval should be increased to more than 72 hours. In a
cohort study, urgent/emergency procedure was found as a predictor of CIN (OR=4,
p<0.0001) (Bartholomew et al., 2004). The higher risk of developing CIN in patients with ur‐
gent status was irrespective of baseline renal function.
2.3.2.2. Use of intra-aortic balloon pump
Using intra-aortic balloon pump may signify a very high-risk population due to very se‐
vere  coronary  atherosclerosis  and/or  indicate  a  role  of  atheroembolism.  In  208  consecu‐
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tive acute myocardial infarction patients undergoing percutaneous coronary intervention,
use of intra-aortic balloon pump was a risk predictor of CIN (OR=15.51, p<0.0001) (Mar‐
enzi et al., 2004). In a study, it has demonstrated that, intra-aortic balloon pump use is an
independent predictor of CIN in patients with chronic kidney disease (OR=2.27, p=0.004)
(Dangas et  al.,  2005).  In another study,  it  was found that  the use of  intra-aortic  balloon
pump was  a  risk  factor  for  CIN requiring  dialysis  after  PCI  (OR=1.94)  (Gruberg  et  al.,
2001).  In  another  derivation and validation cohort  study,  intra-aortic  balloon pump use
was a risk for CIN in patients undergoing coronary intervention (OR=5.1, p<0.0001) (Bar‐
tholomew et al., 2004).
2.3.2.3. Bypass graft intervention and delayed reperfusion
Procedures  with  bypass  angiography  and  intervention  may  be  associated  with  higher
complexity, longer duration, and limited success, thus indicating an unstable post-proce‐
dural period with impaired cardiac output. Gruberg et al. showed that the risk of CIN re‐
quiring  dialysis  after  PCI  was  increased  with  bypass  graft  intervention  (OR=4.94)
(Gruberg et al.,  2001). In a study of 208 acute myocardial infarction patients undergoing
primary PCI,  the risk of  CIN was increased if  the time-to-reperfusion is  ≥6 h (OR=2.51,
p=0.04) (Marenzi et al., 2004)
2.3.3. Contrast medium-related risk factors
2.3.3.1. Increased dose of contrast medium
According to different sources, the relatively safe cutoff point of contrast amount varies
from 70 ml up to 220ml. However, doses as low as 20 to 30 ml are capable of inducing CIN.
In a study that patients undergoing coronary angiography, each 100 ml of contrast medium
administered was associated with a significant increase of 12% in the risk of CIN (OR=1.12,
p=0.02) (Rihal et al., 2002). Marenzi et al. showed that contrast volume >300 ml is an inde‐
pendent risk for CIN (OR=2.80, p=0.02) (Marenzi et al., 2004). In another study patients with
preexisting renal failure revealed a 10-fold risk of CIN when more than 125 ml of contrast
media was administered (Taliercio et al., 1986).
2.3.3.2. High-osmolar and ionic CM
Most  side  effects  attributable  to  contrast  medias  are  related to  hypertonicity.  Currently,
four main types of contrast media are used in routine practice today, including nonionic
low-osmolar,  ionic  low-osmolar,  nonionic  iso-osmolar,  and  ionic  high-osmolar  contrast
media.  In a large study which comparing the non-ionic low-osmolality agent  iohexol  to
the ionic high-osmolality agent meglumine/sodium diatrizoate in patients with pre-exist‐
ing  renal  dysfunction  undergoing  angiography,  patients  with  renal  insufficiency  receiv‐
ing  diatrizoate  were  3.3  times  as  likely  to  develop  CIN  compared  to  those  receiving
iohexol  (Rudnick  et  al.,  1995).  NEPHRIC trial  is  a  randomized,  prospective  study com‐
paring the nonionic iso-osmolar CM iodixanol with the nonionic low-osmolar CM iohex‐
ol  in 129 renal impairment patients with diabetes undergoing coronary or aorto-femoral
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angiography.  The  incidence  of  CIN was  3% in  the  iodixanol  group and 26% in  the  io‐
hexol group (p=0.002) (Aspelin et  al.,  2003).  In another randomized study, the renal tol‐
erance  of  iodixanol  and  iohexol  was  compared  in  124  patients  with  creatinine  >1.7
mg/dl.  The  incidence  of  CIN  was  3.7%  in  iodixanol  group  and  10%  in  iohexol  group
(p>0.05)  (Chalmers  et  al.,  1999).  The  available  data  do  not  provide  clear  evidence  that
the whole iso-osmolar CM class offers an improvement over the low-osmolar CM class.
Other studies with iodixanol  in renal  failure patients  have shown a higher incidence of
CIN  than  that  observed  in  the  NEPHRIC  study  (21%  in  the  RAPPID  trial,  30%  in  the
CONTRAST trial)  (Baker et  al.,  2003:  Stone et  al.,  2003).  In addition to their  osmolarity,
contrast  medias  are  characterized as  ionic  versus  non-ionic.  Small  clinical  trials  of  low-
risk  patients  undergoing  coronary  angiography  have  shown little  difference  in  the  risk
of CIN between the 2 types of CM. However, a randomized trial of 1196 patients under‐
going coronary angiography showed that non-ionic CM reduced the incidence of CIN in
patients with preexisting renal disease with or without diabetes (Rudnick et al., 1995). In
addition,  symptomatic or hemodynamic adverse drug events have been shown to occur
less often with non-ionic,  low-osmolality CM compared with ionic,  high-osmolality CM.
In  high-risk  patients,  it  is  reasonable  to  don’t  use  the  high-osmolar  and  ionic  CM  to
minimize the risk of CIN.
2.3.3.3. Intra-arterial administration of the contrast media
Intra-arterial contrast administration is a risk for CIN. This effect is thought to be due to the
fact that the acute intra renal concentration of CM is much higher after intra arterial rather
than intravenous injection.
2.3.4. Scoring method to predict high risk patients for CIN
Mehran et  al.  developed a  simple  scoring  method that  integrates  eight  baseline  clinical
variables to assess the risk of CIN after percutaneous coronary intervention (PCI). These
are  hypotension  (score  5),  use  of  intra-aortic  balloon  pump  (score  5),  congestive  heart
failure  (score  5),  serum  creatinine>1.5  mg/dl  (score  4),  age>75  years  (score  4),  anemia
(score 3), diabetes mellitus (score 3), and volume of CM (score 1 per 100 ml). If the total
score is 5 or less, the risk category is low; if the total score is 16 or higher, the risk cate‐
gory is very high (Mehran et al., 2004).
2.4. Prevention Strategies for CIN
Extracellular volume expansion with intravenous saline or sodium bicarbonate, minimizing
the dose of CM, using low-osmolar non-ionic CM instead of high osmolar ionic CM, stop‐
ping the intake of nephrotoxic drugs and avoiding short intervals between procedures re‐
quiring CM have all been shown to be effective in reducing CIN. Alternatives to ordinary
CM, such as carbon dioxide or gadolinium chelates, can be used in patients at high risk of
CIN (Table 2).
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Clinical evidence advocating their use Don’t use With conflicting or limited
evidence
Extracellular volume expansion Nonsteroidal anti-inflammatory drugs,
COX-2 inhibitors, aminoglycoside,
cisplatin
Acetylcystein
Saline or sodium bicarbonate Loop diuretics Theophylline
Low or iso-osmolar contrast Mannitol Calcium channel blockers
Minimizing the dose of contrast Multiple use of contrast within 72 h Fenoldopam
Alternative imaging techniques Large doses of contrast Captopril
Monitoring serum creatinine High-osmolar contrast Ascorbic acid
Delaying contrast procedures until
hemodynamic status is corrected
Metformin usage especially in patients
with renal failure
Atrial natriuretic peptide
≥48 h between contrast procedures Endothelin antagonist
PGE1
Hemofiltration
Nebivolol
Statins
B-type natriuretic peptide
Pentoxifylline
Table 2. Prevention strategies for contrast-induced nephropathy in high-risk patients
2.4.1. Volume expansion
Volume expansion is the single most important measure that has been documented to be
beneficial in preventing CIN. A standardized saline hydration protocol has been proven ef‐
fective in reducing the risk of CIN and should be used routinely. The most widely accepted
protocol is administering isotonic saline at 1 to 1.5 ml/kg/h beginning 6 to 12 hours prior to
the procedure and continuing for up to 12 hours following contrast administration. In a
randomized trial, two different hydration regimens were compared in 1620 patients under‐
going coronary interventions. They showed that the incidence of CIN was significantly low‐
er among patients given an isotonic saline solution than among those given a hypotonic
saline solution (0.7% vs. 2.0% respectively, p=0.04) (Mueller et al., 2002). In another trial, a
total of 119 patients with serum creatinine exceeding 1.1 mg/dl were randomized to receive
isotonic solution of sodium bicarbonate (n=59) or isotonic saline (n=60) at a rate of 3 ml/kg/h
for 1 hour before and 1 ml/kg/h for 6 hours after contrast administration. CIN developed in
only 1 patient (1.7%) compared with 8 patients (13.6%) in the saline group (p=0.02) (Merten
et al., 2004). The authors postulated that a reduction in oxidative injury may have conferred
protection against CIN. However, further studies are required to clarify the role of hydra‐
tion with sodium bicarbonate in preventing CIN. In a prospective study, the effect of combi‐
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nation intravenous and oral volume supplementation on the development of CIN was
studied in 425 patients undergoing percutaneous coronary intervention. Patients were ran‐
domly assigned to receive hydration with either isotonic or half-isotonic. In addition pa‐
tients were encouraged to drink plenty of fluids (at least 1500 ml). They found that applying
the combination of intravenous and oral volume supplementation results in a very low inci‐
dence of CIN (1.4%) (Mueller et al., 2005). Most studies have found that hydration alone is
better than hydration combined with a diuretic. In a study, 78 patients with serum creati‐
nine >1.6 mg/dl were randomized to three groups: hydration alone, hydration with mannitol
and hydration with furosemide. Half-isotonic saline was used for hydration. CIN occurred
in 11%, 28% and 40% of patients in the three groups, respectively (p=0.02), thus showing
that forced diuresis is of no benefit in preventing CIN. In a meta-analysis it was found that
the administration of sodium bicarbonate is superior to the administration of saline alone in
the prevention of CIN (Solomon et al., 1994). The effectiveness of sodium bicarbonate treat‐
ment to prevent CIN in high-risk patients remains uncertain.
2.4.2. N-acetylcysteine
Antioxidant N-acetylcysteine (NAC) might scavenge oxygen free radicals,  thus attenuate
the  cytotoxic  effects  of  CM.  NAC may also  have  direct  vasodilating effects  on the  kid‐
neys through an increase in the biologic effects of nitric oxide. Tepel et al. were evaluat‐
ed the effects of NAC (600 mg orally twice daily), at first time, in 83 patients undergoing
computed tomography.  Two percent of  the patients  in the NAC group had CIN versus
21% in the placebo group (p=0.01) (Tepel et al., 2000). Since then, a number of trials have
been published. Results from these trials have been inconsistent. In a randomized, place‐
bo-controlled study it  was found that NAC is  protective against  CIN Fifty-four patients
were  randomized to  receive  either  600  mg of  NAC twice  daily  for  4  doses  or  placebo.
The  incidence  of  CIN  was  8%  in  the  NAC  group  versus  45%  in  the  placebo  group
(p=0.005) (Diaz-Sandoval et al.,  2002). In addition to oral administration, intravenous ad‐
ministration of NAC to protect against CIN has also been evaluated. In a study, Baker et
al. randomly assigned 80 patients to receive either NAC infusion (n=41) versus saline in‐
fusion  (n=39).  CIN  developed  in  only  2  (5%)  of  patients  in  the  NAC  group  compared
with 8 (21%) in the saline group (p=0.04) (Baker et al., 2003). The authors concluded that
NAC infusion protects against CIN. In a meta-analysis, evaluating more than 800 patients
at  high risk of  developing CIN also documented a positive impact of  NAC prophylaxis
on  CIN (Birck  et  al.,  2003).  In  another  meta-analysis,  nine  randomized controlled  trials
were included and the difference in mean change in creatinine between the NAC treated
group and controls was -0.27 mg/dl. The relative risk of developing CIN was 0.43 in sub‐
jects randomized to NAC. They suggest that NAC helps prevent declining renal function
and CIN (Liu et al., 2005). In contrast to these reports, some studies failed to find a signif‐
icant effect of NAC on the occurrence of CINA total of 183 patients with preexisting re‐
nal insufficiency undergoing contrast study were randomly assigned to receive NAC at a
dose of 600 mg twice daily on the day before and the day of the contrast study plus sal‐
ine  infusion or  saline  alone.  The  incidence  of  CIN was  6.5% in  the  NAC group versus
11% in the control group (p=0.22) (Briguori  et  al.,  2002).  In a multi  centric double blind
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clinical trial 156 patients undergoing coronary angiography or percutaneous coronary in‐
tervention with creatinine clearance <50 ml/min were randomly assigned to receive N-ace‐
tylcysteine 600 mg orally twice daily for two days or placebo. Sixteen patients developed
CIN. Eight of 77 patients (10.4%) in the NAC group and eight of 79 patients (10.1%) in
the placebo group (p=1.00). No difference was observed in the change in endogenous cre‐
atinine clearance, p=0.28). They concluded that oral NAC did not prevent CIN in patients
at low to moderate risk undergoing cardiac catheterisation with ionic low osmolality CM
(Gomes  et  al.,  2005).  In  another  study,  50  patients  undergoing  elective  diagnostic  coro‐
nary angiography with serum creatinine values above 1.3 mg/dl were included and CIN
was detected in 3 of 25 patients (12%) in the NAC group and 2 of 25 patients (8%) in the
control group (p>0.05). It was detected that in patients planned to undergo elective diag‐
nostic coronary angiography with renal dysfunction, oral NAC and hydration before the
procedure was not more effective than hydration alone in the prevention of CIN (Gulel et
al.,  2005).  A  direct  renoprotective  effect  of  NAC remains  questionable.  To  date,  only  a
few trials described the effects of NAC not only on serum creatinine but also on clinical
end points. The serum creatinine can be decrease in administration of NAC without reno‐
protective effect. In a prospective study, NAC was given at a dose of 600 mg every 12 h
for a total of four doses to the volunteers with a normal renal function who did not re‐
ceive  contrast  agent.  There  was  a  significant  decrease  of  the  mean  serum  creatinine
(p<0.05) and a significant increase of the GFR (p<0.02), whereas the cystatin C concentra‐
tion did not change significantly (Hoffmann et al., 2004). In patients undergoing emergen‐
cy  diagnostic  procedures,  in  which  a  full  hydration  protocol  is  not  possible,  an
abbreviated  hydration  regimen plus  oral  or  intravenous  administration  of  NAC can  be
recommended. NAC may be of benefit mostly in high-risk patients. If NAC is to be used
as a preventative measure, it  should be given at a dose of 600 mg orally twice daily on
the day before and day of the procedure.
2.4.3. Ascorbic acid
Prophylactic oral administration of ascorbic acid may protect against CIN. In a randomized,
placebo-controlled trial in 231 patients with serum creatinine ≥1.2 mg/dl who undergoing
coronary angiography showed that the use of ascorbic acid was associated with a significant
reduction in the rate of CIN. CIN occurred in 11 of the 118 patients (9%) in the ascorbic acid
group and in 23 of the 113 patients (20%) in the placebo group (OR=0.38; p=0.02) (Spargias et
al., 2004). Further prospective studies are needed to validate these preliminary results.
2.4.4. Fenoldopam
Fenoldopam mesylate is a selective dopamine-1 receptor agonist that produces systemic,
peripheral and renal arterial vasodilatation. Several investigators have reported a positive
impact of fenoldopam against CIN in small studies. In a placebo-controlled, double-blind,
multicenter  trial,  315  patients  with  creatinine  clearance  of  less  than  60  ml/min  were
randomized  to  receive  fenoldopam  infusion  [0.05  µg/kg/min  titrated  to  0.1  µg/kg/min
(n=157)]  or matching placebo (n=158).  CIN occurred in 33.6% of patients in the fenoldo‐
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pam group compared with 30.1% of patients in the placebo group (p=0.61) (Stone et al.,
2003).  The  authors  concluded  that  fenoldopam did  not  protect  against  CIN.  In  2  other
large studies comparing fenoldopam with NAC treatment with fenoldopam either had a
similar, non significant effect as that of NAC or was inferior to it (Allaqaband et al., 2002;
Briguori  et  al.,  2004).  The  routine  use  of  fenoldopam  cannot  be  recommended  at  the
present time.
2.4.5. Adenosine antagonists
CM stimulate the intrarenal secretion of adenosine, which binds to the renal adenosine re‐
ceptor and acts as a potent vasoconstrictor, reducing renal blood flow and increasing the
generation of oxygen free radicals as it is metabolized to xanthine and hypoxanthine. Theo‐
phylline and aminophylline, adenosine antagonists, have also been studied in the preven‐
tion of CIN in a number of trials. Studies with these agents have used varying doses and
dosage forms and yielded conflicting results (Erley et al., 1999; Kapoor et al., 2001). Based on
the conflicting information found in clinical studies, adenosine antagonists should not be
routinely used in patients as a preventative measure at this time.
2.4.6. Calcium channel blockers
The calcium channel  antagonists  verapamil  and diltiazem have been found to attenuate
the renal vasoconstrictor response after exposure to CM. However,  when the efficacy of
the felodipine, nitrendipine and nifedipine was evaluated, results were inconsistent. Two
small studies performed the use of sublingual nifedipine given prior to contrast adminis‐
tration. Patients (n=20) who received sublingual nifedipine did not have a significant in‐
crease in serum creatinine, while those in the placebo group did (Rodicio et al., 1990). In
another  study,  patients  (n=30)  who received nifedipine had an increase in  renal  plasma
flow following administration of contrast,  while patients in the placebo group had a de‐
crease in  renal  flow (Russo et  al.,  1990).  One other  study showed that  nitrendipine use
cause  a  significant  reduction in  the  GFR in  the  placebo group compared to  little  or  no
change in GFR in the nitrendipine group (Neumayer et al., 1989). In another study, 27 pa‐
tients with normal to moderately reduced renal function underwent femoral angiography
randomized to receive either oral felodipine or placebo. Patients in the felodipine group
had a significant increase in serum creatinine from baseline, while patients in the placebo
group  did  not  demonstrate  a  similar  increase  (Spangberg-Viklund  et  al.,  1996).  More
large-scale trials are needed before calcium channel blockers can be routinely recommend‐
ed in patients prior to CM administration.
2.4.7. Prostaglandin E1
PGE1 has vasodilatory effects that may be beneficial in preventing CIN. In one study, 130
patients were randomly assigned to receive either placebo or one of three doses of PGE1. The
increase in serum creatinine level was smaller in all of the three PGE1 groups than in the pla‐
cebo group, but the difference was significant only in the medium-dose (20 ng/kg/min) of
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PGE1 group (Koch et al., 2000). More studies need to be done to better understand the role of
prostaglandin E1, but results from this pilot study appear promising.
2.4.8. Atrial Natriuretic Peptide (ANP)
ANP may prevent CIN by increasing renal blood flow. In a study, ANP was included in one
of the four arms. In which dopamine, mannitol, and ANP caused an increase in CIN in dia‐
betic patients as compared to saline alone (Weisberg et al., 1994). In another trial patients
were randomized to one of four treatment arms: fluid alone or one of three doses of ANP.
Results showed no statistically significant differences in the incidence of CIN between any
of the four treatment arms (Kurnik et al., 1998) Based on these results and the limited clinical
data, ANP cannot be advocated in the prevention of CIN.
2.4.9. Endothelin antagonists
Endothelin-1 is a potent endogenous vasoconstrictor, is thought to play a role in the de‐
velopment of CIN. Endothelin-1 has two primary receptors. In animal studies, endothelin-
A antagonists were shown to reduce the incidence of CIN (Liss et al., 2003). However, in
a randomized study of  158 patients,  the  use of  a  mixed endothelin-A and B antagonist
was  associated with  a  significantly  higher  incidence  of  CIN than was  placebo (56% vs.
29%, p=0.002)  (Wang et  al.,  2000).  Endothelin antagonists  currently have no role in pre‐
vention of CIN.
2.4.10. Low-dose of dopamine
At low doses (1-3 mcg/kg/min),  dopamine activates two types of dopamine (DA) recep‐
tors,  DA-1 and DA-2. Activation of the DA-1 receptor results in an increase in natriure‐
sis and renal blood flow. Since dopamine, at low doses, is believed to be more selective
for the DA-1 receptors,  it  has been investigated in the prevention of CIN. Kapoor et  al.
randomized 40  patients  with diabetes  scheduled to  undergo a  coronary angiography to
either dopamine or placebo control.  None of the patients in the dopamine group devel‐
oped CIN compared to 50% of patients receiving placebo (Kapoor et al., 2002). In anoth‐
er  prospective,  randomized  trial,  Hans  et  al.  evaluated  55  patients  (40%  had  diabetes)
with  chronic  renal  insufficiency.  Patients  were  randomized  to  receive  dopamine  or  an
equal  volume  of  saline.  The  group  receiving  dopamine  had  a  significantly  lower  inci‐
dence of CIN as compared to the control group (Hans et al., 1998). In contrast to the tri‐
als  showing  a  potential  benefit  of  dopamine,  other  studies  have  failed  to  demonstrate
this benefit. Abizaid et al. performed a randomized, prospective study involving patients
with renal insufficiency who underwent coronary angioplasty. Patients were randomized
to  continue  with  the  saline,  receive  aminophylline  in  addition  to  the  saline,  or  receive
dopamine  plus  saline.  In  the  dopamine  plus  saline  group,  50%  of  patients  developed
CIN, while only 30% of the patients in the saline-alone group developed CIN. This dif‐
ference did not reach statistical significance, but it appeared that use of dopamine might
worsen outcomes (Abizaid et al.,  1999).  Low-dose dopamine use cannot be supported at
this time.
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2.4.11. Statins
Whether additional benefits can be achieved with the use of statin in decreasing the risk of
CIN remains undetermined. In a recent meta analysis of randomised controlled trials com‐
paring statin pretreatment with non-statin pretreatment for the prevention of CIN, it was
found that, the incidence of CIN was not significantly lower in statin pretreatment group as
compared with control group (RR=0.76, p=0.30) (Zhang et al., 2011). The current cumulative
evidence suggests that statin pretreatment may neither prevent CIN nor reduce the need for
renal replacement therapy.
2.4.12. Nebivolol
In an experimental study we demonstrated that nebivolol have a protective role against
CIN. Nebivolol leads to a decrease in the systemic and renal oxidative stres (p=0.001) and an
increase in renal nitrite production (p=0.027). In addition, contrast-induced proteinuria, pro‐
teinaceous cast (p< 0.001), and tubular necrosis (p=0.001) are restored by nebivolol (Toprak
et al., 2008). Two recent human studies demonstrated the protective effect of nebivolol on
CIN. One of the study showed that the use of oral nebivolol for one week at a dose of 5 mg
per day decrease the incidence of CIN in patients who underwent coronary angiography
with renal dysfunction (p=0.03) (Avci et al., 2011). Another more recent study showed that
the use of oral nebivolol for 4 days at a dose of 5 mg per day is protective against nephrotox‐
ic effects of CM in patients who underwent coronary angiography or ventriculography (Gu‐
nebakmaz et al., 2012). More large-scale trials are needed before nebivolol can be routinely
recommended in prevention of CIN.
2.4.13. Hemofiltration and hemodialysis
Currently available data do not support use of prophylactic hemodialysis for prevention
of CIN. In a trial of 113 patients, reported that CIN occurred in 24% of the hemodialysis
group as compared with 16% of non-hemodialysis group (Vogt et al., 2001). Clinically rel‐
evant events also were not different in two groups. Only continuous venovenous hemofil‐
tration has been shown to protect against CIN. In a study, 114 patients with chronic renal
failure  undergoing  percutaneous  coronary  intervention  were  divided in  two groups:  56
patients received normal saline and 58 patients underwent hemofiltration at a rate of 1000
ml/h  (Marenzi  et  al.,  2003).  Hemofiltration  seems  to  have  a  protective  effect,  including
significant  reduction  in  in-hospital  and  1-year  mortality  compared  with  routine  hydra‐
tion. The mechanisms of this benefit are not clear. Further studies are needed to confirm
the results of this trial.
2.4.14. New types of contrast medias
Gadolinium-enhanced magnetic resonance coronary angiography is a non-invasive method
for evaluation of coronary arteries. It has been suggested that gadolinum-based CM could
be used in stead of iodinated CM for radiological examinations in patients with significant
renal impairment. However, its use has been questioned on the basis of reports of nephro‐
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toxicity and its association with nephrogenic systemic fibrosis, a rare and serious syndrome
that involves fibrosis of skin, joints, eyes, and internal organs. In a study by Hoffmann et al.
the effect of gadopentetate dimeglumine (iodine-based CM) was studied in 181 patients
with normal renal function and the effect of gadolinium was studied in 198 patients with
pre-excisting renal failure. There was no statistically significant change in serum creatinine
concentration after gadopentetate dimeglumine. In contrary, serum creatinine levels de‐
creased significantly after the administration of gadolinium (p<0.01) (Hoffmann et al., 2005).
In a retrospective study, the safety of gadolinium was evaluated in 91 patients with stage 3
and 4 renal failure who underwent angiographic MRI procedures. Eleven of 91 patients de‐
veloped CIN (12.1%) (Ergun et al., 2006). In another randomized study gadobutrol, a gadoli‐
nium-based CM, was compared with standard iohexol, an iodinated CM, in 21 patients with
renal dysfunction. The incidence of CIN was 50% in gadobutrol group and 45% in iohexol
group (p=0.70). In this study, gadolinium showed no benefit over iohexol in patients with
severely impaired renal function (Erley et al., 2004). More studies need to be done to better
understand the role of gadolinum on CIN. Ultrasound contrast agents are micro-bubbles
which produce acoustic enhancement. They are pharmacologically almost inert and safe.
3. Conclusion
The development of CIN is associated with adverse outcomes including prolonged hospital‐
ization, the potential need for renal replacement therapy, and most important, increased
mortality. The treatment of established CIN is limited to supportive measures and dialysis.
For this reason, screening for high-risk patients before CM including -cardiac procedures
and taking the appropriate prophylactic regimens is important in reducing CIN. Pre-exist‐
ing renal dysfunction, especially when secondary to diabetic nephropathy, is the most im‐
portant risk factor. Extra cellular volume expansion and use of low osmolar CM are the two
most effective measures to prevent CIN. Acetylcysteine may use in high-risk patients, and
nebivolol may use as a new prophylactic agent for CIN, but this finding has not been uni‐
form or always demonstrated by currently available trials.
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